[go: up one dir, main page]

US20100210864A1 - Process for the preparation of n-arylmorpholinones - Google Patents

Process for the preparation of n-arylmorpholinones Download PDF

Info

Publication number
US20100210864A1
US20100210864A1 US12/706,109 US70610910A US2010210864A1 US 20100210864 A1 US20100210864 A1 US 20100210864A1 US 70610910 A US70610910 A US 70610910A US 2010210864 A1 US2010210864 A1 US 2010210864A1
Authority
US
United States
Prior art keywords
denotes
hal
atoms
het
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/706,109
Inventor
Dieter Dorsch
Bertram Cezanne
Werner Mederski
Christos Tsaklakidis
Hanns Wurziger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/567,846 external-priority patent/US20060287450A1/en
Application filed by Individual filed Critical Individual
Priority to US12/706,109 priority Critical patent/US20100210864A1/en
Publication of US20100210864A1 publication Critical patent/US20100210864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the invention relates to a process for the preparation of compounds of the formula I
  • the invention had the object of finding novel improved processes for the preparation of precursors of factor Xa inhibitors.
  • Factor Xa inhibitors can be employed for combating and preventing thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
  • thromboembolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
  • Factor Xa is one of the proteases involved in the complex process of blood coagulation. Factor Xa catalyses the conversion of prothrombin into thrombin. Thrombin cleaves fibrinogen into fibrin monomers, which, after crosslinking, make an elementary contribution to thrombus formation. Activation of thrombin may result in the occurrence of thromboembolic diseases. However, inhibition of thrombin may inhibit the fibrin formation involved in thrombus formation.
  • the inhibition of thrombin can be measured, for example by the method of G. F. Cousins et al. in Circulation 1996, 94, 1705-1712.
  • Inhibition of factor Xa can thus prevent the formation of thrombin.
  • the inhibition of factor Xa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods.
  • a suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
  • the inhibition of factor Xa can be measured, for example by the method of T. Nara et al. in Thromb. Haemostas. 1994, 71, 314-319.
  • Coagulation factor VIIa initiates the extrinsic part of the coagulation cascade after binding to tissue factor and contributes to the activation of factor X to give factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus subsequent thrombin formation.
  • the inhibition of factor VIIa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods.
  • a conventional method for the measurement of the inhibition of factor VIIa is described, for example, by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.
  • Coagulation factor IXa is generated in the intrinsic coagulation cascade and is likewise involved in the activation of factor X to give factor Xa. Inhibition of factor IXa can therefore prevent the formation of factor Xa in a different way.
  • the inhibition of factor IXa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods.
  • a suitable method is described, for example, by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.
  • arylamines so long as they have a pK a of less than or equal to 3, also react with 2-chlorodioxene to give 2-(2-chloroethoxy)acetamides.
  • reaction it is advantageous to add an acid, for example a Brönsted acid, such as hydrochloric acid, or a Lewis acid, or alternatively to add 2,2-dichlorodioxene, a compound which, as is known from the literature (R. K. Summerbell, H. E. Lunk, J. Am. Chem. Soc. 79, p. 4802, 1957), readily dissociates into hydrogen chloride and 2-chlorodioxene.
  • the reaction can be carried out in many solvents, for example toluene, acetonitrile, dioxane, but also in mass, i.e. without solvent.
  • Typical reaction temperatures are 0 to 150° C., generally around 80° C., for example between 70 and 90° C.
  • chloroethoxyacetamides can preferably be cyclised to give morpholinones using weak bases, such as, for example, caesium carbonate or potassium carbonate, in a suitable solvent, such as, for example, acetonitrile.
  • weak bases such as, for example, caesium carbonate or potassium carbonate
  • a suitable solvent such as, for example, acetonitrile.
  • A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.
  • A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl.
  • A′ preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl or trifluoromethyl.
  • Cycloalkyl has 3-7 C atoms and preferably denotes cyclopropyl, cyclobutyl, cyclopentyl or cylohexyl.
  • Hal preferably denotes F, Cl or Br, but also I.
  • R 1 preferably denotes NO 2 , CN, COOH, COOR 3 , COR 3 or Cl.
  • R 2 preferably denotes H, Hal or A.
  • R 3 preferably denotes H, A′ or —[C(R 5 ) 2 ] n —Ar.
  • R 4 preferably denotes A.
  • Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-proylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl-phenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methyl-aminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-phenyl, o-, m- or
  • Ar preferably denotes, for example, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR 5 , SO 2 A, COOR 5 or CN.
  • Ar particularly preferably denotes, for example, phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO 2 A, SO 2 NH 2 , COOR 5 or CN, such as, for example, phenyl, 2-methylsulfonylphenyl, 2-aminosulfonylphenyl, 2-, 3- or 4-chlorophenyl, 4-methylphenyl, 4-bromophenyl, 3-fluoro-4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4-ethoxyphenyl, 2-methoxyphenyl, 3-cyanophenyl or 4-ethoxycarbonylphenyl.
  • Ar very particularly preferably denotes unsubstituted phenyl.
  • Het is unsubstituted or mono- or disubstituted by Hal, A, OR 5 , N(R 5 ) 2 , NO 2 , CN, COOR 5 , CON(R 5 ) 2 , NR 5 COA, NR 5 SO 2 A, COR 5 , SO 2 N(R 5 ) 2 , S(O) n A and/or carbonyl oxygen ( ⁇ O) and denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2,4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-y
  • heterocyclic radicals may also be partially or fully hydrogenated.
  • Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-
  • n preferably denotes 0 or 1.
  • m preferably denotes 0, 1 or 2.
  • the invention preferably relates to a process according to Claim 1 for the preparation of compounds of the formula I in which
  • R 1 denotes NO 2 , CN, COOR 3 , COR 3 or Cl
  • R 2 denotes H, Hal or A.
  • R 1 denotes NO 2 , CN, COOR 3 , CON(R 3 ) 2 , COR 3 , CF 3 , F or Cl
  • R 2 denotes H, Hal or A′
  • R 3 denotes H, A′ or —[C(R 5 ) 2 ] n —Ar
  • Ar denotes phenyl
  • R 5 denotes H or A′
  • A′ denotes unbranched or branched alkyl having 1-6 C atoms
  • Hal denotes F, Cl, Br or I
  • n denotes 0, 1 or 2.
  • the compounds of the formula I can preferably be obtained by, in a first step a), reacting compounds of the formula II with 5-chloro-2,3-dihydro-1,4-dioxin to give a compound of the formula III.
  • the reaction is generally carried out in an inert solvent, but can also be carried out without solvent in mass.
  • an acid for example a Brönsted acid, such as hydrochloric acid, or a Lewis acid
  • 2,2-dichlorodioxene a compound which, as is known from the literature (R. K. Summerbell, H. E. Lunk, J. Am. Chem. Soc. 79, p. 4802, 1957), readily dissociates into hydrogen chloride and 2-chlorodioxene.
  • the reaction time is between a few minutes and 14 days, preferably between one and ten hours
  • the reaction temperature is between about 0° and 150°, normally between 20° and 130°, preferably between 60° and 110°, very particularly preferably between 70° and 90° C.
  • Suitable inert solvents are, for example, water; hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or
  • the reaction is generally carried out in an inert solvent, preferably in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate.
  • an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate preferably in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate.
  • weak bases such as caesium carbonate or potassium carbonate.
  • the reaction time is between a few minutes and 14 days, preferably between one and twenty hours
  • the reaction temperature is between about 0° and 150°, normally between 0° and 90°, preferably between 10° and 70°, particularly preferably between 20° and 50° C.
  • Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethyl
  • Process steps a) and b) can also be carried out as a one-pot reaction.
  • the temperature of the solution is lowered and an excess of alkali metal carbonate (typically 1.5 to 4 equivalents) is added and the reaction mixture is stirred until conversion is complete.
  • a base of the formula I can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, followed by evaporation.
  • Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts.
  • inorganic acids for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-
  • compounds of the formula I can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate).
  • bases for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate.
  • physiologically acceptable organic bases such as, for example, ethanolamine.
  • the invention also relates to the intermediate compounds of the formula III
  • the intermediate compounds are important for the preparation of the compounds of the formula I.
  • the invention also relates to the intermediate compounds in which
  • R 1 denotes NO 2 or CN
  • R 2 denotes H, Hal or A, and salts thereof.
  • R 1 denotes NO 2 or CN
  • R 2 denotes H, Hal or A
  • R 3 denotes H, A, —[C(R 5 ) 2 ] n —Ar or —[C(R 5 ) 2 ] n —Het, and salts thereof.
  • Ar denotes phenyl, and salts thereof.
  • R 4 denotes A, and salts thereof.
  • R 1 denotes NO 2 or CN
  • R 2 denotes H, Hal or A′
  • R 3 denotes H, A′ or —[C(R 5 ) 2 ] n —Ar
  • Ar denotes phenyl
  • R 5 denotes H or A′
  • A′ denotes unbranched or branched alkyl having 1-6 C atoms
  • Hal denotes F, Cl, Br or I
  • n denotes 0, 1 or 2
  • m denotes 0, 1 or 2, and salts thereof.
  • R 1 denotes NO 2
  • R 2 denotes H, Hal or A′
  • R 3 denotes H, A′ or —[C(R 5 ) 2 ] n —Ar
  • Ar denotes phenyl
  • R 5 denotes H or A′
  • A′ denotes unbranched or branched alkyl having 1-6 C atoms
  • Hal denotes F, Cl, Br or I
  • n denotes 0, 1 or 2
  • m denotes 0, 1 or 2 and salts thereof.
  • the invention also relates to a process for the preparation of intermediate compounds of the formula III
  • the compound of the formula III is optionally converted into its salt.
  • R 1 denotes NO 2 or CN
  • R 2 denotes H, Hal or A.
  • R 1 denotes NO 2 or CN
  • R 2 denotes H
  • R 3 denotes H, A, —[C(R 5 ) 2 ] n —Ar or —[C(R 5 ) 2 ] n -Het.
  • R 1 denotes NO 2 or CN
  • R 2 denotes H, Hal or A′
  • R 3 denotes H, A′ or —[C(R 5 ) 2 ] n —Ar
  • Ar denotes phenyl
  • R 5 denotes H or A′
  • A′ denotes unbranched or branched alkyl having 1-6 C atoms
  • Hal denotes F, Cl, Br or I
  • n denotes 0, 1 or 2
  • m denotes 0, 1 or 2.
  • MS Mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Process for the preparation of compounds of the formula (I) in which X has the meaning indicated in Patent Claim 1, and precursors thereof.

Description

  • THIS APPLICATION IS A DIVISIONAL OF U.S. SER. No. 11/567,846, FILED 10 Feb. 2006.
  • The invention relates to a process for the preparation of compounds of the formula I
  • Figure US20100210864A1-20100819-C00001
  • in which
    X denotes
  • Figure US20100210864A1-20100819-C00002
    • R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2, CF3, F or Cl,
    • R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,
    • R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R5 denotes H or A′,
    • Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,
    • Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
    • A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    • A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
    • Hal denotes F, Cl, Br or I,
    • n denotes 0, 1 or 2,
    • m denotes 0, 1, 2, 3 or 4,
      and salts thereof, characterised in that
    • a) a compound of the formula II

  • X—NH2  II
  • in which
    X has the meaning indicated above,
    is reacted with 5-chloro-2,3-dihydro-1,4-dioxin
  • Figure US20100210864A1-20100819-C00003
  • to give a compound of the formula III
  • Figure US20100210864A1-20100819-C00004
  • in which
    X has the meaning indicated above,
    • b) then a compound of the formula III is cyclised to give a compound of the formula I,
      and
    • c) the latter is optionally converted into its salt
      by converting a base or acid of the formula I into one of its salts.
  • The invention had the object of finding novel improved processes for the preparation of precursors of factor Xa inhibitors.
  • Compared with known processes from the prior art, the process according to the invention is shorter and more efficient.
  • Factor Xa inhibitors can be employed for combating and preventing thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
  • Factor Xa is one of the proteases involved in the complex process of blood coagulation. Factor Xa catalyses the conversion of prothrombin into thrombin. Thrombin cleaves fibrinogen into fibrin monomers, which, after crosslinking, make an elementary contribution to thrombus formation. Activation of thrombin may result in the occurrence of thromboembolic diseases. However, inhibition of thrombin may inhibit the fibrin formation involved in thrombus formation.
  • The inhibition of thrombin can be measured, for example by the method of G. F. Cousins et al. in Circulation 1996, 94, 1705-1712.
  • Inhibition of factor Xa can thus prevent the formation of thrombin.
  • The inhibition of factor Xa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
  • The inhibition of factor Xa can be measured, for example by the method of T. Nara et al. in Thromb. Haemostas. 1994, 71, 314-319.
  • Coagulation factor VIIa initiates the extrinsic part of the coagulation cascade after binding to tissue factor and contributes to the activation of factor X to give factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus subsequent thrombin formation.
  • The inhibition of factor VIIa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A conventional method for the measurement of the inhibition of factor VIIa is described, for example, by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.
  • Coagulation factor IXa is generated in the intrinsic coagulation cascade and is likewise involved in the activation of factor X to give factor Xa. Inhibition of factor IXa can therefore prevent the formation of factor Xa in a different way.
  • The inhibition of factor IXa and the measurement of the anticoagulant and antithrombotic activity can be determined by conventional in-vitro or in-vivo methods. A suitable method is described, for example, by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.
  • A correlation between tissue factor TF/factor VIIa and the development of various types of cancer has been indicated by T. Taniguchi and N. R. Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis of Pancreatic Cancer), 57-59. The publications listed below describe an antitumoural action of TF-VII and factor Xa inhibitors for various types of tumour:
  • K. M. Donnelly et al. in Thromb. Haemost. 1998; 79: 1041-1047;
    E. G. Fischer et al. in J. Clin. Invest. 104: 1213-1221 (1999);
    B. M. Mueller et al. in J. Clin. Invest. 101: 1372-1378 (1998);
    M. E. Bromberg et al. in Thromb. Haemost. 1999; 82: 88-92.
    WO 02/057236 describes other processes and morpholinone precursors.
  • The following methods for the preparation of 2-(2-chloroethoxy)acetamides are known in the literature:
  • Figure US20100210864A1-20100819-C00005
  • This method is described, for example, in U.S. Pat. No. 3,074,939, BE 776767 and DE 1922613.
  • Figure US20100210864A1-20100819-C00006
  • This method is described, for example, in G. May, D. Peteri, Arzneim.-Forsch. (Drug Res.) 23, 718 (1973).
  • Figure US20100210864A1-20100819-C00007
  • This method is described, for example, in DE 2150075.
  • However, these methods have disadvantages. Thus, many reaction steps are necessary or the starting materials are expensive.
  • M. J. Astle, J. D. Welks, J. Org. Chem. 26, 4325 (1961) disclose the following reaction:
  • Figure US20100210864A1-20100819-C00008
  • We have found, surprisingly, that arylamines, so long as they have a pKa of less than or equal to 3, also react with 2-chlorodioxene to give 2-(2-chloroethoxy)acetamides.
  • Figure US20100210864A1-20100819-C00009
  • In view of M. J. Astle, J. D. Welks, J. Org. Chem. 26, 4325 (1961), this is unexpected since amines, such as ammonia, benzylamine, 8-amino-quinoline or 4-methoxyaniline, do not react or react very poorly.
  • Comparison of pKa values:
  •
    Benzylamine 9.5
    Ammonia 9.24
    8-Aminoquinoline 0.7 (NH2 group) and 4.0 (quinoline nitrogen).
    The basic quinoline nitrogen prevents the
    reaction.
    4-Methoxyaniline 5.4
    4-Nitroaniline 1.0
    4-Cyanoaniline 1.7
    3-Nitroaniline 2.5
    2-Methyl-4-nitroaniline 1.04
    Methyl 4-aminobenzoate 1.5
    4-Aminobenzophenone 2.2
    2-Nitroaniline −0.23
  • In the reaction, it is advantageous to add an acid, for example a Brönsted acid, such as hydrochloric acid, or a Lewis acid, or alternatively to add 2,2-dichlorodioxene, a compound which, as is known from the literature (R. K. Summerbell, H. E. Lunk, J. Am. Chem. Soc. 79, p. 4802, 1957), readily dissociates into hydrogen chloride and 2-chlorodioxene. The reaction can be carried out in many solvents, for example toluene, acetonitrile, dioxane, but also in mass, i.e. without solvent. Typical reaction temperatures are 0 to 150° C., generally around 80° C., for example between 70 and 90° C.
  • The advantage of this process lies in the ready accessibility of 2-chlorodioxene or 2,2-dichlorodioxane.
  • Figure US20100210864A1-20100819-C00010
  • The preparation of 2,3-dichlorodioxane is described, for example, in M. lyoda et al, Heterocycles, 54, p. 833, 2001. The thermal elimination of hydrogen chloride is described in U.S. Pat. No. 2,756,240. This method gives 2-chlorodioxene, which is contaminated with a certain proportion of 2,2-dichlorodioxane (typically 5 to 50%).
  • N. V. Kuznetsov, I. I. Krasavtsev, Soy. Prog. Chem. (Engl. Transl.) 44, p. 77, 1987, describe methods for the preparation of 2-chlorodioxene from 2,3-dichlorodioxane using sodium hydroxide.
  • Figure US20100210864A1-20100819-C00011
  • The cyclisation of chloroethoxyacetamides to give morpholinones has hitherto only been described in two publications, in DE 922613 and L. Fumagalli et al. Pharmazie 30, 78 (1975).
  • Both cases involve triiodobenzoic acid and triiodophenylalkanoic acid derivatives.
  • Figure US20100210864A1-20100819-C00012
  • However, this process is only suitable for substrates which are water-soluble, as in the above documents, in which R always contains a free carboxyl group.
  • We have found that chloroethoxyacetamides can preferably be cyclised to give morpholinones using weak bases, such as, for example, caesium carbonate or potassium carbonate, in a suitable solvent, such as, for example, acetonitrile.
  • Above and below, A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl.
  • A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl or trifluoromethyl.
  • A′ preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl or trifluoromethyl.
  • Cycloalkyl has 3-7 C atoms and preferably denotes cyclopropyl, cyclobutyl, cyclopentyl or cylohexyl.
  • Hal preferably denotes F, Cl or Br, but also I.
  • R1 preferably denotes NO2, CN, COOH, COOR3, COR3 or Cl.
    R2 preferably denotes H, Hal or A.
    R3 preferably denotes H, A′ or —[C(R5)2]n—Ar.
    R4 preferably denotes A.
  • Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-proylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl-phenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methyl-aminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-phenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)-phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)-phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methylsulfonyl)phenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-di-fluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-di-chloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.
  • Ar preferably denotes, for example, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, SO2A, COOR5 or CN. Ar particularly preferably denotes, for example, phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO2A, SO2NH2, COOR5 or CN, such as, for example, phenyl, 2-methylsulfonylphenyl, 2-aminosulfonylphenyl, 2-, 3- or 4-chlorophenyl, 4-methylphenyl, 4-bromophenyl, 3-fluoro-4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4-ethoxyphenyl, 2-methoxyphenyl, 3-cyanophenyl or 4-ethoxycarbonylphenyl.
  • Ar very particularly preferably denotes unsubstituted phenyl.
  • Het is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O) and denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2,4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.
  • The heterocyclic radicals may also be partially or fully hydrogenated. Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1,4-oxazinyl, furthermore preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylene-dioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)-phenyl or alternatively 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo-furanyl.
  • n preferably denotes 0 or 1.
    m preferably denotes 0, 1 or 2.
  • The invention preferably relates to a process according to Claim 1 for the preparation of compounds of the formula I in which
  • R1 denotes NO2, CN, COOR3, COR3 or Cl,
    R2 denotes H, Hal or A.
  • Preference is furthermore given to a process according to Claim 1 or 2 for the preparation of compounds of the formula I in which
    • R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2, CF3, For Cl,
    • R2 denotes H, Hal or A,
    • R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het.
  • Preference is furthermore given to a process according to Claim 1 for the preparation of compounds of the formula I in which Ar denotes phenyl.
  • Preference is furthermore given to a process for the preparation of compounds of the formula I in which R4 denotes A.
  • Preference is furthermore given to a process for the preparation of compounds of the formula I in which
  • R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, CF3, F or Cl,
    R2 denotes H, Hal or A′,
    R3 denotes H, A′ or —[C(R5)2]n—Ar,
    Ar denotes phenyl,
    R5 denotes H or A′,
    A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    Hal denotes F, Cl, Br or I,
    n denotes 0, 1 or 2.
  • Very particular preference is given to a process according to Claim 1 for the preparation of compounds selected from the group
    • 4-(4-nitrophenyl)-3-oxomorpholine,
    • 4-(3-nitrophenyl)-3-oxomorpholine,
    • 4-(2-nitrophenyl)-3-oxomorpholine,
    • 2-methyl-4-(4-nitrophenyl)-3-oxomorpholine,
    • 4-(4-methoxycarbonylphenyl)-3-oxomorpholine,
    • 4-(4-benzoylphenyl)-3-oxomorpholine.
  • Preference is furthermore given to a process according to one or more of Claims 1-6 for the preparation of compounds of the formula I in which the amine of the formula II has a pKa value≦3.
  • The compounds of the formula I can preferably be obtained by, in a first step a), reacting compounds of the formula II with 5-chloro-2,3-dihydro-1,4-dioxin to give a compound of the formula III.
  • The reaction is generally carried out in an inert solvent, but can also be carried out without solvent in mass.
  • It is advantageous to add an acid, for example a Brönsted acid, such as hydrochloric acid, or a Lewis acid, or alternatively to add 2,2-dichlorodioxene, a compound which, as is known from the literature (R. K. Summerbell, H. E. Lunk, J. Am. Chem. Soc. 79, p. 4802, 1957), readily dissociates into hydrogen chloride and 2-chlorodioxene.
  • Depending on the conditions used, the reaction time is between a few minutes and 14 days, preferably between one and ten hours, the reaction temperature is between about 0° and 150°, normally between 20° and 130°, preferably between 60° and 110°, very particularly preferably between 70° and 90° C.
  • Suitable inert solvents are, for example, water; hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents. Particular preference is given to acetonitrile.
  • In a second step b), compounds of the formula III are cyclised to give the compounds of the formula I.
  • The reaction is generally carried out in an inert solvent, preferably in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate. Very particular preference is given to weak bases, such as caesium carbonate or potassium carbonate.
  • Depending on the conditions used, the reaction time is between a few minutes and 14 days, preferably between one and twenty hours, the reaction temperature is between about 0° and 150°, normally between 0° and 90°, preferably between 10° and 70°, particularly preferably between 20° and 50° C.
  • Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents, particular preference is given to acetonitrile.
  • Process steps a) and b) can also be carried out as a one-pot reaction. When the amine and 2-chlorodioxene have reacted completely, the temperature of the solution is lowered and an excess of alkali metal carbonate (typically 1.5 to 4 equivalents) is added and the reaction mixture is stirred until conversion is complete.
  • A base of the formula I can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, followed by evaporation. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and -disulfonic acids, laurylsulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used for the isolation and/or purification of the compounds of the formula I.
  • On the other hand, compounds of the formula I can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate).
  • It is also possible to use physiologically acceptable organic bases, such as, for example, ethanolamine.
  • The invention also relates to the intermediate compounds of the formula III
  • Figure US20100210864A1-20100819-C00013
  • in which
    X denotes
  • Figure US20100210864A1-20100819-C00014
    • R1 denotes NO2 or CN,
    • R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,
    • R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R5 denotes H or A′,
    • Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2,
    • NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,
    • Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
    • A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    • A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
    • Hal denotes F, Cl, Br or I,
    • n denotes 0, 1 or 2,
    • m denotes 0, 1, 2, 3 or 4,
      and salts thereof.
  • The intermediate compounds are important for the preparation of the compounds of the formula I.
  • The preferred meanings of the radicals correspond to those as indicated above, unless expressly stated otherwise.
  • The invention also relates to the intermediate compounds in which
  • R1 denotes NO2 or CN,
    R2 denotes H, Hal or A,
    and salts thereof.
  • Preference is furthermore given to intermediate compounds in which
  • R1 denotes NO2 or CN,
    R2 denotes H, Hal or A,
    R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    and salts thereof.
  • Preference is furthermore given to intermediate compounds in which
  • Ar denotes phenyl,
    and salts thereof.
  • Preference is furthermore given to intermediate compounds in which
  • R4 denotes A,
    and salts thereof.
  • Particular preference is given to intermediate compounds in which
  • R1 denotes NO2 or CN,
    R2 denotes H, Hal or A′,
    R3 denotes H, A′ or —[C(R5)2]n—Ar,
    Ar denotes phenyl,
    R5 denotes H or A′,
    A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    Hal denotes F, Cl, Br or I,
    n denotes 0, 1 or 2,
    m denotes 0, 1 or 2,
    and salts thereof.
  • Particular preference is given to intermediate compounds in which
  • R1 denotes NO2,
    R2 denotes H, Hal or A′,
    R3 denotes H, A′ or —[C(R5)2]n—Ar,
    Ar denotes phenyl,
    R5 denotes H or A′,
    A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    Hal denotes F, Cl, Br or I,
    n denotes 0, 1 or 2,
    m denotes 0, 1 or 2,
    and salts thereof.
  • The invention also relates to a process for the preparation of intermediate compounds of the formula III
  • in which
  • Figure US20100210864A1-20100819-C00015
  • X denotes
  • Figure US20100210864A1-20100819-C00016
    • R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2,
    • CF3, F or Cl,
    • R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,
    • R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R5 denotes H or A′,
    • Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,
    • Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
    • A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    • A denotes branched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
    • Hal denotes F, Cl, Br or I,
    • n denotes 0, 1 or 2,
    • m denotes 0, 1, 2, 3 or 4,
      and salts thereof, characterised in that
    • a) a compound of the formula II

  • X—NH2  II
  • in which
    X has the meaning indicated above,
    is reacted with 5-chloro-2,3-dihydro-1,4-dioxin
    and
  • Figure US20100210864A1-20100819-C00017
  • the compound of the formula III is optionally converted into its salt.
  • The conditions of the process, in particular the preferred ones, are the same as indicated under the process for the preparation of the compound of the formula I.
  • The preferred meanings of the radicals correspond to those as indicated above, unless expressly stated otherwise.
  • Preference is given to a process for the preparation of intermediate compounds of the formula III
  • in which
    • R1 denotes NO2 or CN,
    • R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,
    • R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
    • R5 denotes H or A′,
    • Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,
    • Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
    • A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    • A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
    • Hal denotes F, Cl, Br or I,
    • n denotes 0, 1 or 2,
    • m denotes 0, 1, 2, 3 or 4.
  • Preference is furthermore given to a process for the preparation of intermediate compounds of the formula III
  • in which
    R1 denotes NO2 or CN,
    R2 denotes H, Hal or A.
  • Preference is furthermore given to a process for the preparation of intermediate compounds of the formula III
  • in which
    R1 denotes NO2 or CN,
    R2 denotes H, Hal or A,
    R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n-Het.
  • Preference is furthermore given to a process for the preparation of intermediate compounds of the formula III
  • in which
    Ar denotes phenyl.
  • Preference is also given to a process for the preparation of intermediate compounds of the formula III
  • in which
    R4 denotes A.
  • Particular preference is given to a process for the preparation of intermediate compounds of the formula III
  • in which
    R1 denotes NO2 or CN,
    R2 denotes H, Hal or A′,
    R3 denotes H, A′ or —[C(R5)2]n—Ar,
    Ar denotes phenyl,
    R5 denotes H or A′,
    A′ denotes unbranched or branched alkyl having 1-6 C atoms,
    Hal denotes F, Cl, Br or I,
    n denotes 0, 1 or 2,
    m denotes 0, 1 or 2.
    Above and below, all temperatures are indicated in ° C.
    Mass spectrometry (MS): EI (electron impact ionisation) M+;
    ESI (electrospray ionisation) (M+H)+;
    FAB (fast atom bombardment) (M+H)+
    • EXAMPLE 1 4-(4-Nitrophenyl)-3-oxomorpholine
  • The preparation is carried out analogously to the following scheme:
  • Figure US20100210864A1-20100819-C00018
  • 1.1 Without Solvent:
  • 1.53 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 1:1) are added to 1.00 g (7.24 mmol) of 4-nitroaniline, and the mixture is heated to 80° C. with stirring. A solid brown mass forms within one hour and becomes liquid again and crystallises within the following 12 hours. The crude product is recrystallised from ethanol with addition of water, giving 1.80 g of 2-(2-chloroethoxy)-N-(4-nitrophenyl)acetamide (“A1”) as yellowish crystals, m.p. 101-102° C. 1H-NMR (d6-DMSO): δ=3.82 (m; 4H), 4.23 (s; 2H), 7.91 (d, J=9 Hz, 2H), 8.23 (d, J=9 Hz, 2H), 10.34 (s, 1H).
  • 1.2 In Acetonitrile:
  • 310 mg of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 1:1) are added to a solution of 276 mg (2.00 mmol) of 4-nitroaniline in 2 ml of acetonitrile, and the solution is heated at 80° C. with stirring for 18 hours. The reaction mixture is evaporated, and the residue is recrystallised from ethanol/water: 360 mg of “A1” as yellowish crystals.
  • 1.3 1 kg of “A1” is dissolved in 5 litres of acetonitrile at room temperature, 835 g of potassium carbonate are added, and the mixture is stirred at this temperature for 18 hours. The mixture is warmed to 50° and worked up analogously to Example 6, giving 4-(4-nitrophenyl)-3-oxomorpholine (“A2”), m.p. 150-152°.
    • EXAMPLE 2 4-(4-Nitro-2-methylphenyl)-3-oxomorpholine
  • 1.05 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 1:1) are added to a solution of 1.10 g (7.24 mmol) of 2-methyl-4-nitroaniline in 20 ml of THF, and the mixture is heated to the boil. The solvent is distilled off, and the residue, a brown viscous liquid, is heated at 80° C. for 18 hours. After cooling, the residue is recrystallised from toluene/tert-butyl methyl ether: 1.50 g of 2-(2-chloroethoxy)-N-(2-methyl-4-nitrophenyl)acetamide as yellowish crystals, m.p. 113-114° C. 1H-NMR (d6-DMSO): δ=2.35 (s; 3H), 3.82 (m; 4H), 4.23 (s; 2H), 8.05 (d, J=8 Hz, 1H) 8.09 (dd, J=9 Hz, J=1 Hz, 1H), 8.16 (d, J=1 Hz, 1H), 9.33 (s, 1H).
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(4-nitro-2-methylphenyl)-3-oxomorpholine, ESI 237.
    • EXAMPLE 3 4-(2-Nitrophenyl)-3-oxomorpholine
  • 1.12 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 89:11) are added to 1.12 g (8.12 mmol) of 2-nitroaniline, and the mixture is heated to 80° C. with stirring. A viscous liquid forms, which is stirred for 3 hours. On cooling to room temperature, the product crystallises: 2.1 g of 2-(2-chloroethoxy-N-(2-nitrophenyl)acetamide as yellowish crystals. 1H-NMR (d6-DMSO): δ=3.84 (m; 4H), 4.25 (s; 2H), 7.35 (t, J=8 Hz, 1H), 7.77 (t, J=8 Hz, 1H), 8.14 (d, J=8 Hz, 1H), 8.30 (d, J=8 Hz, 1H), 10.74 (s, 1H).
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(2-nitrophenyl)-3-oxomorpholine, ESI 223.
    • EXAMPLE 4 4-(4-Cyanophenyl)-3-oxomorpholine
  • A mixture of 959 mg (8.12 mmol) of 4-aminobenzonitrile and 1.12 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 89:11) is heated at 80° C. with stirring for 18 hours. On cooling to room temperature, the product crystallises: 1.9 g of 2-(2-chloroethoxy)-N-(4-cyanophenyl)-acetamide as yellowish crystals 1H-NMR (d6-DMSO): δ=3.82 (m; 4H), 4.19 (s; 2H), 7.78 (d, J=8 Hz, 2H), 7.85 (d, J=8 Hz, 2H), 10.22 (s, 1H).
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(4-cyanophenyl)-3-oxomorpholine, ESI 203.
    • EXAMPLE 5 4-(4-Methoxycarbonylphenyl)-3-oxomorpholine
  • A mixture of 1.23 mg (8.12 mmol) of methyl 4-aminobenzoate and 1.12 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 89:11) is heated at 80° C. with stirring for 18 hours. On cooling to room temperature, the product crystallises: 2.2 g of methyl 4-[2-(2-chloroethoxy)acetylamino]benzoate as yellowish crystals. 1H-NMR (d6-DMSO): δ=3.82 (m; 7H), 4.20 (s; 2H), 7.82 (d, J=8 Hz, 2H), 7.93 (d, J=8 Hz, 2H), 10.15 (s, 1H).
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(4-methoxycarbonylphenyl)-3-oxomorpholine, ESI 236.
    • EXAMPLE 6 One-Pot Reaction for the Preparation of “A2”
  • 6.40 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) are added to a solution of 6.00 g (24.9 mmol) of 4-nitroaniline in 40 ml of acetonitrile, and the mixture is stirred at 80° C. for 18 hours. The reaction solution is cooled to 40° C., 18.0 g (130 mmol) of potassium carbonate are added, and the mixture is stirred at this temperature for 14 hours.
  • The reaction mixture is filtered, the residue is washed well with acetonitrile, and the filtrate is evaporated. The residue is recrystallised from acetonitrile: 8.2 g of brownish crystals (“A2”), m.p. 150-152° C. 1H-NMR (d6-DMSO): δ=3.86 (t, J=5 Hz; 2H), 4.02 (t, J=5 Hz; 2H), 4.28 (s; 2H), 7.77 (d, J=9 Hz, 2H), 8.28 (d, J=9 Hz, 2H).
    • EXAMPLE 7 4-(3-Nitrophenyl)-3-oxomorpholine
  • A mixture of 1.12 g (8.12 mmol) of 3-nitroaniline and 1.11 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) is heated at 80° C. with stirring for 24 hours, giving 2.1 g of 2-(2-chloroethoxy)-N-(3-nitrophenyl)-acetamide as brownish oil. ESI 259.
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(3-nitrophenyl)-3-oxomorpholine, ESI 223.
    • EXAMPLE 8 4-(4-Benzoylphenyl)-3-oxomorpholine
  • A mixture of 1.60 g (8.12 mmol) of 4-aminobenzophenone and 1.11 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) is heated at 80° C. with stirring for 24 hours, giving 2.6 g of N-(4-benzoylphenyl)-2-(2-chloroethoxy)acetamide as brown oil. ESI 318.
  • The cyclisation is carried out analogously to 1.3,
  • giving 4-(4-benzoylphenyl)-3-oxomorpholine, ESI 282.
    • EXAMPLE 9 4-(3-Fluorophenyl)-3-oxomorpholine
  • Figure US20100210864A1-20100819-C00019
  • A mixture of 12.0 g (108 mmol) of 3-fluoraniline and 16 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) is heated at 100° C. for 24 hours. The mixture is allowed to cool, and excess 2-chlorodioxene is removed under reduced pressure, giving 25 g of 2-(2-chloroethoxy)-N-(3-fluorophenyl)acetamide as brown oil; ESI 232. This oil is dissolved in 400 ml of acetonitrile, and 84.7 g (260 mmol) of caesium carbonate are added. The suspension formed is stirred at room temperature for 18 hours. The reaction mixture is filtered, and the filtrate is evaporated, giving 21.0 g of 4-(3-fluorophenyl)morpholin-3-one as brown oil; ESI 196. 1H-NMR (d6-DMSO): δ=3.77 (t, J=5 Hz; 2H), 3.97 (t, J=5 Hz; 2H), 4.23 (s; 2H), 7.11 (dddd, J1=8 Hz, J2=8 Hz, J3=2 Hz, J4=0.5 Hz, 1H), 7.26 (ddd, J1=8 Hz, J2=2 Hz, J3=0.5 Hz, 1H), 7.34 (ddd, J1=10 Hz, J2=2 Hz, J3=2 Hz, 1H), 7.45 (ddd, J1=8 Hz, J2=8 Hz, J3=7 Hz, 1H).
    • EXAMPLE 10 4-(3-Methyl-4-nitrophenyl)-3-oxomorpholine
  • Figure US20100210864A1-20100819-C00020
  • 12.8 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) are added to a solution of 10.0 g (65.7 mmol) of 3-methyl-4-nitroaniline in 250 ml of acetonitrile, and the mixture is stirred at 80° C. for 66 hours. The reaction solution is cooled to room temperature, 42.8 g (131 mmol) of caesium carbonate are added, and the mixture is stirred at room temperature for 18 hours. The reaction mixture is filtered, the residue is washed well with acetonitrile, and the filtrate is evaporated. The residue is recrystallised from a little acetonitrile, giving 12.8 g (83%) of 4-(3-methyl-4-nitrophenyl)morpholin-3-one as yellowish solid. ESI 236. 1H-NMR (d6-DMSO): δ=2.54 (s; 2H), δ=3.82 (t, J=5 Hz; 2H), 4.00 (t, J=5 Hz; 2H), 4.25 (s; 2H), 7.57 (m; 2H), 8.04 (d, J.=8 Hz; 1H).
    • 4-(2-Chloro-5-fluoro-4-nitrophenyl)-3-oxomorpholine is obtained analogously
  • Figure US20100210864A1-20100819-C00021
    • EXAMPLE 11 4-(2-Bromo-5-nitrophenyl)-3-oxomorpholine is obtained analogously to Example 7
  • Figure US20100210864A1-20100819-C00022
    • 4-(2-Methoxycarbonyl-5-nitrophenyl)-3-oxomorpholine is obtained analogously to Example 7
  • Figure US20100210864A1-20100819-C00023

Claims (15)

1.-14. (canceled)
15. A compound of the formula III
in which
Figure US20100210864A1-20100819-C00024
X denotes
Figure US20100210864A1-20100819-C00025
R1 denotes NO2 or CN,
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, CORS, SO2N(R3)2 or SO2R4,
R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R5 denotes H or A′,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COORS, CON(R5)2, NR5COA, NR5SO2A, CORS, SO2N(R5)2 or S(O)nA,
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, CORS, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1, 2, 3 or 4,
or a salt thereof.
16. A compound according to claim 15 in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A,
or a salt thereof.
17. A compound according to claim 15, in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A,
R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
or a salt thereof.
18. A compound according to claim 15 in which
Ar denotes phenyl,
or a salt thereof.
19. A compound according to claim 15 in which
R4 denotes A,
or a salt thereof.
20. A compound according to claim 15 in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A′,
R3 denotes H, A′ or —[C(R5)2]n—Ar,
Ar denotes phenyl,
R5 denotes H or A′,
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1 or 2,
or a salt thereof.
21. A compound according to claim 20 in which
R1 denotes NO2,
R2 denotes H, Hal or A′,
R3 denotes H, A′ or —[C(R5)2]n—Ar,
Ar denotes phenyl,
R5 denotes H or A′,
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1 or 2,
or a salt thereof.
22. A process for the preparation of a compound of the formula III
Figure US20100210864A1-20100819-C00026
in which
X denotes
Figure US20100210864A1-20100819-C00027
R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2, CF3, F or Cl,
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,
R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R5 denotes H or A′,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, ORS, N(R5)2, NO2, CN, COORS, CON(R5)2, NR5COA, NR5SO2A, CORS, SO2N(R5)2 or S(O)nA,
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, CORS, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1, 2, 3 or 4,
and salts thereof, characterised in that
a) a compound of the formula II

X—NH2  II
in which
X has the meaning indicated above,
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin
Figure US20100210864A1-20100819-C00028
and
the compound of the formula III is optionally converted into its salt.
23. A process according to claim 22 for the preparation of a compound of the formula III in which
R1 denotes NO2 or CN,
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COORS, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, —[C(R5)2]n—Ar, —[C(R5)2]n—Het, —[C(R5)2]n-cycloalkyl, CORS, SO2N(R3)2 or SO2R4,
R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R4 denotes A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het,
R5 denotes H or A′,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (═O),
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by —CH═CH— groups and/or in addition 1-7H atoms may be replaced by F,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1, 2, 3 or 4.
24. A process according to claim 23 for the preparation of a compound of the formula III in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A.
25. A process according to claim 23 for the preparation of a compound of the formula III in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A,
R3 denotes H, A, —[C(R5)2]n—Ar or —[C(R5)2]n—Het.
26. A process according to claim 23 for the preparation of a compound of the formula III in which
Ar denotes phenyl.
27. A process according to claim 23 for the preparation of a compound of the formula III in which
R4 denotes A.
28. A process according to claim 23 for the preparation of a compound of the formula III in which
R1 denotes NO2 or CN,
R2 denotes H, Hal or A′,
R3 denotes H, A′ or —[C(R5)2]n—Ar,
Ar denotes phenyl,
R5 denotes H or A′,
A′ denotes unbranched or branched alkyl having 1-6 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1 or 2,
m denotes 0, 1 or 2.
US12/706,109 2003-08-11 2010-02-16 Process for the preparation of n-arylmorpholinones Abandoned US20100210864A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/706,109 US20100210864A1 (en) 2003-08-11 2010-02-16 Process for the preparation of n-arylmorpholinones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10336716.0 2003-08-11
DE10336716A DE10336716A1 (en) 2003-08-11 2003-08-11 Process for the preparation of N-aryl-morpholinones
US10/567,846 US20060287450A1 (en) 2003-08-11 2004-07-14 Immobilizable ruthenium catalysts having n-heterocyclic carbene ligands
US12/706,109 US20100210864A1 (en) 2003-08-11 2010-02-16 Process for the preparation of n-arylmorpholinones

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/567,846 Division US8110194B2 (en) 2005-12-07 2006-12-07 CTLA-4 antibody dosage escalation regimens

Publications (1)

Publication Number Publication Date
US20100210864A1 true US20100210864A1 (en) 2010-08-19

Family

ID=34177411

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/567,848 Expired - Fee Related US7687624B2 (en) 2003-08-11 2004-07-16 Process for the production of N-arylmorpholinones
US12/706,109 Abandoned US20100210864A1 (en) 2003-08-11 2010-02-16 Process for the preparation of n-arylmorpholinones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/567,848 Expired - Fee Related US7687624B2 (en) 2003-08-11 2004-07-16 Process for the production of N-arylmorpholinones

Country Status (19)

Country Link
US (2) US7687624B2 (en)
EP (1) EP1654240B1 (en)
JP (1) JP4668903B2 (en)
KR (1) KR101119940B1 (en)
CN (1) CN100537549C (en)
AR (1) AR045244A1 (en)
AT (1) ATE344252T1 (en)
AU (1) AU2004265056B2 (en)
BR (1) BRPI0413484A (en)
CA (1) CA2535412C (en)
DE (2) DE10336716A1 (en)
DK (1) DK1654240T3 (en)
ES (1) ES2275233T3 (en)
MX (1) MXPA06001567A (en)
PL (1) PL1654240T3 (en)
PT (1) PT1654240E (en)
RU (1) RU2343149C2 (en)
WO (1) WO2005016899A1 (en)
ZA (1) ZA200602068B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211654B (en) * 2013-08-13 2017-03-29 联化科技（台州）有限公司 A kind of preparation method and intermediate of Rivaroxaban intermediate
CN103804222A (en) * 2014-02-25 2014-05-21 湖北迅达药业股份有限公司 Synthetic method of 4-(4-aminophenyl)-3-morpholinone and intermediate thereof
CN103804221B (en) * 2014-02-25 2016-09-14 湖北迅达药业股份有限公司 A kind of Preparation Method And Their Intermediate of 4-(4-aminophenyl)-3-morpholone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087582A1 (en) * 2001-01-19 2004-05-06 Dieter Dorsch Phenyl derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074939A (en) * 1961-06-26 1963-01-22 American Home Prod 10-(2-morpholinoethoxyacetyl) pheno-thiazine and its preparation
CH512247A (en) * 1968-05-02 1971-09-15 Bracco Ind Chimica Spa New X-ray contrast media and processes for their production
DE19743435A1 (en) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidine derivatives
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087582A1 (en) * 2001-01-19 2004-05-06 Dieter Dorsch Phenyl derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Merderski et al (Bioorg Med Chem Lett 14:5817-5822, 2004) *

Also Published As

Publication number Publication date
AU2004265056B2 (en) 2011-03-17
CA2535412C (en) 2012-08-28
US20060217550A1 (en) 2006-09-28
AU2004265056A1 (en) 2005-02-24
JP4668903B2 (en) 2011-04-13
CN100537549C (en) 2009-09-09
HK1095145A1 (en) 2007-04-27
RU2343149C2 (en) 2009-01-10
ES2275233T3 (en) 2007-06-01
DE502004001923D1 (en) 2006-12-14
KR101119940B1 (en) 2012-03-19
CA2535412A1 (en) 2005-02-24
AR045244A1 (en) 2005-10-19
ZA200602068B (en) 2007-05-30
EP1654240B1 (en) 2006-11-02
EP1654240A1 (en) 2006-05-10
WO2005016899A1 (en) 2005-02-24
DK1654240T3 (en) 2007-03-26
CN1832933A (en) 2006-09-13
BRPI0413484A (en) 2006-10-17
PT1654240E (en) 2007-02-28
DE10336716A1 (en) 2005-03-10
RU2006107291A (en) 2007-09-20
JP2007501818A (en) 2007-02-01
PL1654240T3 (en) 2007-02-28
US7687624B2 (en) 2010-03-30
KR20060066086A (en) 2006-06-15
MXPA06001567A (en) 2006-05-15
ATE344252T1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
US6492368B1 (en) Benzamidine derivatives as factor XA inhibitors
US20100210864A1 (en) Process for the preparation of n-arylmorpholinones
JP4732757B2 (en) Carboxamide
JP5542066B2 (en) Process for preparing 3,6-dihydro-L, 3,5-triazine derivatives from metformin and paraaldehyde derivatives
SK12152001A3 (en) Pyrazole-3-on-derivative as factor xa inhibitors
US7598241B2 (en) Carboxamide derivatives and their use as factor Xa inhibitors
HK1095145B (en) Process for the preparation of n-arylmorpholinones
RU2340595C2 (en) Method of obtaining monoalkylaminoketones
US20030166694A1 (en) Glycinamides
US20030199698A1 (en) Carbamic acid esters as inhibitors of factor xa
CZ20001183A3 (en) The benzamidine derivative as a factor XA inhibitor, a process for its preparation, its use and a pharmaceutical composition containing it

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE